Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 23

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Optimal Dosing Regimen of Osteoporosis Drugs in Relation to Food Intake as the Key for the Enhancement of the Treatment Effectiveness—A Concise Literature Review

Wiesner, Agnieszka, Szuta, Mariusz, Galanty, Agnieszka, Paśko, Paweł·2021·Foods
DOI 10.3390/foods10040720
Open this paper in CoChat — free account

Abstract

Bisphosphonates and selective estrogen receptor modulators (SERMs) represent the two most important groups of medications taken orally and employed in osteoporosis treatment. Effectiveness of the therapy may be affected by poor patient adherence, in particular, due to the inconvenient dosing regimen of oral bisphosphonates. With this review we aimed to assess the effects that food, beverages, and dietary supplements consumed during treatment, along with the dosing regimens, may have on pharmacokinetics and pharmacodynamics of oral drugs employed in treating osteoporosis; we also aimed to shape the recommendations valuable for professional patients’ counseling and education, to provide appropriate dosing regimens in order to improve adherence to the therapy. Food, beverages such as coffee, juices, and mineral water, as well as dietary supplements containing multivalent cations, e.g., calcium, magnesium, aluminium, iron, showed to have a deleterious effect on the bioavailability of all the investigated oral bisphosphonates, specifically alendronate, risedronate, ibandronate, minodronate, and etidronate. For risedronate, a delayed-release (DR) tablet was designed to solve the malabsorption problem in the presence of food, hence DR risedronate can be ingested following breakfast. For other oral bisphosphonates, the proper interval between drug and food, beverages, and dietary supplements intake should be maintained to minimize the risk of interactions. The effect of food on pharmacokinetic parameters of selective estrogen receptor modulators (SERMs) was found to be clinically irrelevant.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/foods10040720

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 48

  1. Cramer, 2008, Medication compliance and persistence: Terminology and definitions, Value Health, 11, 44, 10.1111/j.1524-4733.2007.00213.x · DOI · Paper page
  2. Park, 2019, Impact on bisphosphonate persistence and compliance: Daily postprandial administration, J. Bone Metab., 26, 39, 10.11005/jbm.2019.26.1.39 · DOI
  3. Donato, 2019, Adherence to bisphosphonates in the general population: A study in patients referred to a primary care service, Arch. Osteoporos., 14, 10, 10.1007/s11657-019-0593-2 · DOI
  4. Kothawala, 2007, Systematic Review and Meta-analysis of Real-World Adherence to Drug Therapy for Osteoporosis, Mayo Clin. Proc., 82, 1493, 10.1016/S0025-6196(11)61093-8 · DOI · Paper page
  5. Yeam, 2018, A systematic review of factors affecting medication adherence among patients with osteoporosis, Osteoporos. Int., 29, 2623, 10.1007/s00198-018-4759-3 · DOI
  6. Cornelissen, 2020, Interventions to improve adherence to anti-osteoporosis medications: An updated systematic review, Osteoporos. Int., 31, 1645, 10.1007/s00198-020-05378-0 · DOI
  7. Wilcock, 2018, What do we know about the administration of oral bisphosphonates in a hospital setting?, Pharmacoepidemiol. Drug Saf., 27, 3
  8. Paśko, P. (2019). Food-drug interactions among the elderly: Risk assessment and recommendations for patients. Encycl. Biomed. Gerontol., 107–114. · DOI
  9. Eastell, 2019, Pharmacological management of osteoporosis in postmenopausal women: An endocrine society clinical practice guideline, J. Clin. Endocrinol. Metab., 104, 1595, 10.1210/jc.2019-00221 · DOI · Paper page
  10. Ogura, 2004, Clinical trial of risedronate in Japanese volunteers: A study on the effects of timing of dosing on absorption, J. Bone Miner. Metab., 22, 120, 10.1007/s00774-003-0459-x · DOI
  11. Qaseem, 2017, Treatment of Low Bone Density or Osteoporosis to Prevent Fractures in Men and Women: A Clinical Practice Guideline Update From the American College of Physicians, Ann. Intern. Med., 166, 818, 10.7326/M15-1361 · DOI · Paper page
  12. Pazianas, 2013, Eliminating the need for fasting with oral administration of bisphosphonates, Ther. Clin. Risk Manag., 9, 395, 10.2147/TCRM.S52291 · DOI
  13. Byun, 2017, The Efficacy of Bisphosphonates for Prevention of Osteoporotic Fracture: An Update Meta-analysis, J. Bone Metab., 24, 37, 10.11005/jbm.2017.24.1.37 · DOI
  14. Kinov, 2012, Clinical utility of risedronate in postmenopausal osteoporosis: Patient considerations with delayed-release formulation, Int. J. Womens Health, 4, 167, 10.2147/IJWH.S18209 · DOI
  15. Soares, 2016, Bisphosphonates: Pharmacokinetics, bioavailability, mechanisms of action, clinical applications in children, and effects on tooth development, Environ. Toxicol. Pharmacol., 42, 212, 10.1016/j.etap.2016.01.015 · DOI
  16. Cheng, L., and Wong, H. (2020). Food effects on oral drug absorption: Application of physiologically-based pharmacokinetic modeling as a predictive tool. Pharmaceutics, 12. · DOI
  17. Biernacka, 2013, Prediction of bioavailability of selected bisphosphonates using in silico methods towards categorization into biopharmaceutical classification system, Acta Pol. Pharm. Drug Res., 70, 877
  18. Reid, I.R., and Bolland, M.J. (2020). Calcium and/or vitamin D supplementation for the prevention of fragility fractures: Who needs it?. Nutrients, 12. · DOI
  19. Harvey, 2017, The role of calcium supplementation in healthy musculoskeletal ageing: An expert consensus meeting of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Foundat, Osteoporos. Int., 28, 447, 10.1007/s00198-016-3773-6 · DOI
  20. Gertz, 1995, Studies of the oral bioavailability of alendronate, Clin. Pharmacol. Ther., 58, 288, 10.1016/0009-9236(95)90245-7 · DOI · Paper page
  21. Ringe, 2006, Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: An approach to improving correct intake and drug adherence, Drugs Aging, 23, 569, 10.2165/00002512-200623070-00003 · DOI
  22. Akagi, 2011, Influence of mineral water on absorption of oral alendronate in rats, Yakugaku Zasshi, 131, 801, 10.1248/yakushi.131.801 · DOI
  23. Itoh, 2016, Interaction between bisphosphonates and mineral water: Study of oral risedronate absorption in rats, Biol. Pharm. Bull., 39, 323, 10.1248/bpb.b15-00630 · DOI
  24. Pellegrini, 2009, Which water for alendronate administration?, Osteoporos. Int., 20, 1451, 10.1007/s00198-008-0784-y · DOI
  25. Morr, 2006, How much calcium is in your drinking water? A survey of calcium concentrations in bottled and tap water and their significance for medical treatment and drug administration, HSS J., 2, 130, 10.1007/s11420-006-9000-9 · DOI
  26. Azoulay, 2001, Comparison of the mineral content of tap water and bottled waters, J. Gen. Intern. Med., 16, 168, 10.1111/j.1525-1497.2001.04189.x · DOI · Paper page
  27. Imai, 2013, Alendronate sodium hydrate (oral jelly) for the treatment of osteoporosis: Review of a novel, easy to swallow formulation, Clin. Interv. Aging, 8, 681, 10.2147/CIA.S37199 · DOI
  28. Gertz, 1993, Clinical pharmacology of alendronate sodium, Osteoporos. Int., 3, 13, 10.1007/BF01623002 · DOI
  29. Wagener, 2000, Safety and efficacy of alendronate when not taken in the morning. Results of an 8-week prospective study, Eur. J. Geriatr., 2, 35
  30. Mitchell, 1999, The effect of dosing regimen on the pharmacokinetics of risedronate, Br. J. Clin. Pharmacol., 48, 536, 10.1046/j.1365-2125.1999.00035.x · DOI
  31. Zhou, 2015, Pharmacokinetics and Tolerability of Minodronic Acid Tablets in Healthy Chinese Subjects and Food and Age Effects on the Pharmacokinetics, Clin. Ther., 37, 869, 10.1016/j.clinthera.2015.01.015 · DOI
  32. Kendler, 2009, Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis, Osteoporos. Int., 20, 1895, 10.1007/s00198-009-0893-2 · DOI
  33. Agrawal, 2006, Between-meal risedronate does not alter bone turnover in nursing home residents, J. Am. Geriatr. Soc., 54, 790, 10.1111/j.1532-5415.2006.00696.x · DOI · Paper page
  34. Fukase, 2018, Phase I clinical trial of NE-58095 DR, a risedronate delayed-release tablet: Dose escalation and food effect, Jpn. J. Clin. Pharmacol. Ther., 49, 113, 10.3999/jscpt.49.113 · DOI
  35. McClung, 2012, Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet, Osteoporos. Int., 23, 267, 10.1007/s00198-011-1791-y · DOI
  36. McClung, 2013, Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years, Osteoporos. Int., 24, 301, 10.1007/s00198-012-2175-7 · DOI
  37. Soen, 2020, Phase II/III, randomized, double-blind, parallel-group study of monthly delayed-release versus daily immediate-release risedronate tablets in Japanese patients with involutional osteoporosis, J. Bone Miner. Metab., 38, 86, 10.1007/s00774-019-01031-x · DOI
  38. Nakai, 2015, The effect of fasting interval on oral bioavailability of ibandronate, Jpn. Pharmacol. Ther., 43, 1553
  39. McClung, 2003, The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 min before breakfast, Bone, 32, 421, 10.1016/S8756-3282(03)00033-4 · DOI
  40. Ohishi, 2018, Minodronate for the treatment of osteoporosis, Ther. Clin. Risk Manag., 14, 729, 10.2147/TCRM.S149236 · DOI
  41. Matsumoto, 2020, Minodronate, Bone, 137, 115432, 10.1016/j.bone.2020.115432 · DOI
  42. Papaioannou, 2010, 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary, CMAJ, 182, 1864, 10.1503/cmaj.100771 · DOI · Paper page
  43. Fogelman, 1986, Absorption of Oral Diphosphonate in Normal Subjects, Clin. Endocrinol., 24, 57, 10.1111/j.1365-2265.1986.tb03254.x · DOI
  44. Cook, 2000, The time of day that Etidronate is ingested does not influence its therapeutic effect in osteoporosis, Scand. J. Rheumatol., 29, 62, 10.1080/030097400750001824 · DOI
  45. Ryan, 2000, Timing of cyclical etidronate, Clin. Exp. Rheumatol., 18, 609
  46. Jha, 2011, Bioadhesive microspheres for bioavailability enhancement of raloxifene hydrochloride: Formulation and pharmacokinetic evaluation, AAPS PharmSciTech, 12, 650, 10.1208/s12249-011-9619-9 · DOI
  47. Morello, 2003, Pharmacokinetics of Selective Estrogen Receptor Modulators, Clin. Pharmacokinet., 42, 361, 10.2165/00003088-200342040-00004 · DOI
  48. McKeand, 2017, Pharmacokinetics, Dose Proportionality, and Bioavailability of Bazedoxifene in Healthy Postmenopausal Women, Clin. Ther., 39, 1769, 10.1016/j.clinthera.2017.07.012 · DOI

Cited by

See all 23

Metadata

Authors
Wiesner, A., Szuta, M., Galanty, A., & Paśko, P.
Venue
Foods
Publisher
MDPI AG
Published
2021-03-29
Volume
10
Issue
4
Pages
720
ISSN
2304-8158
DOI
10.3390/foods10040720
Cited by
23
References
1
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
Polish Ministry of Education and Science (SONP/SP/461418/2020)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.